Pharmacokinetics and dosing regimens of direct oral anticoagulants in morbidly obese patients: an updated literature review
Y Zhao, M Guo, D Li, W Xu, C Pan… - Clinical and Applied …, 2023 - journals.sagepub.com
Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation
C Escobar-Cervantes, P Díez-Villanueva… - Expert Review of …, 2023 - Taylor & Francis
Introduction In addition to an increased risk of thromboembolic complications, patients with
atrial fibrillation (AF) are at risk for vascular events. Consequently, complete vascular …
atrial fibrillation (AF) are at risk for vascular events. Consequently, complete vascular …
Safety and efficacy of direct oral anticoagulants in comparison to warfarin in obese patients with atrial fibrillation: A systematic review and meta‐analysis
A Adelkhanova, PR Oli, DB Shrestha… - Health Science …, 2024 - Wiley Online Library
Abstract Background and Aim Obesity affects nearly 650 million adults worldwide, and the
prevalence is steadily rising. This condition has significant adverse effects on cardiovascular …
prevalence is steadily rising. This condition has significant adverse effects on cardiovascular …
An instrument to measure atrial fibrillation knowledge in Chinese patients: validation of the Jessa Atrial fibrillation Knowledge Questionnaire
S Chang, W Xu, S Wu, L Desteghe, F Zhang… - Frontiers in …, 2023 - frontiersin.org
Background: There is no validated tool to assess patients' knowledge of oral anticoagulant
therapy in atrial fibrillation in China. Methods: Using a standard translation program, the …
therapy in atrial fibrillation in China. Methods: Using a standard translation program, the …
Comparing the Clinical Outcomes Observed with Rivaroxaban Versus Warfarin for the Management of Obese Patients with Non-valvular Atrial Fibrillation: a …
X Zhuo, J Wang, L Shao - Cardiovascular Drugs and Therapy, 2024 - Springer
Background Atrial fibrillation (AF) is an irregular heart rhythm which is becoming more and
more common in this new era. Obesity is a risk factor for cardiovascular events, and obese …
more common in this new era. Obesity is a risk factor for cardiovascular events, and obese …
[HTML][HTML] The Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients With Atrial Fibrillation: A Network Meta-Analysis
QM Salah, S Bhandari, A Chand, S Khan, SHA Tirmzi… - Cureus, 2023 - ncbi.nlm.nih.gov
Atrial fibrillation (AF) is a cardiac condition characterized by an irregular heart rhythm, which
is increasingly prevalent in the modern era. All international guidelines strongly advise the …
is increasingly prevalent in the modern era. All international guidelines strongly advise the …
Drugs that affect blood coagulation, fibrinolysis and hemostasis
TM Benavides, AL Hulsizer - Side Effects of Drugs Annual, 2022 - Elsevier
A literature review of drugs that affect blood coagulation, fibrinolysis and hemostasis
published in the year 2021 was conducted and yielded 70 systemic reviews, meta-analyses …
published in the year 2021 was conducted and yielded 70 systemic reviews, meta-analyses …